Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 9Phase 4 6Phase 1 5Phase NA 4Phase 1/2 1

Status

Completed 4Unknown 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 1

Conditions

Papillomavirus Infections 5Uterine Cervical Neoplasms 3Condylomata Acuminata 2Vulvar Neoplasms 1Virus Diseases 1Vaginal Neoplasms 1Anus Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Papillomavirus Vaccines × Clear all
NCT03900572 2023-04-13

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Shanghai Zerun Biotechnology Co.,Ltd

Phase 1 Completed
90 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05672966 2023-01-06

Phase I Clinical Trial of a Candidate HPV Vaccine

Wuhan BravoVax Co., Ltd.

Phase 1 Unknown
40 enrolled

Papillomavirus Infections

NCT03085381 2018-09-14

A Phase I Study of Quadrivalent HPV Recombinant Vaccine

Shanghai Bovax Biotechnology Co., Ltd.

Phase 1 Completed
90 enrolled

Papillomavirus Infections

NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

GlaxoSmithKline

Phase 1 Completed
961 enrolled 43 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡